In a landmark deal, Sun Pharmaceutical Industries, India's largest drugmaker, has announced its acquisition of Organon & Co. for $11.75 billion. This acquisition will provide Sun Pharma access to Organon’s extensive portfolio of over 70 products, particularly in women's health and biosimilars, thereby expanding its global footprint. This deal is part of a broader trend of significant mergers and acquisitions in India, which have reshaped the corporate landscape over the past two decades. Noteworthy past deals include Tata Steel's acquisition of Corus for $12 billion in 2007, which transformed Tata Steel into the world's fifth-largest steel producer, and Bharti Airtel's purchase of Zain Africa for $10.7 billion in 2010, which extended its reach into 15 African countries. These transactions highlight India's growing influence in the global market and its capacity for large-scale corporate maneuvers.